Head and Neck Squamous Carcinoma
Conditions
Keywords
head and neck squamous cell carcinoma, Rituximab, recurrent or metastatic
Brief summary
Head and neck squamous cell carcinoma (HNSCC) is an important disease with the incidence of 6th all over the world. In Taiwan it is the fifth of male cancer mortality. Most of the patients were middle age and the impact for economy and society was incredible. For recurrent or metastatic HNSCC, the average life span was around 4-6 months. Most patients just can receive chemotherapy. However the chemotherapy can't have any survival benefit. Recently a study showed the Cetuximab plus chemotherapy with cisplatin and 5-fluorouracil had survival benefit in the recurrent or metastatic HNSCC. However in Taiwan, the cetuximab can't be given by health insurance for the patients of the situation. A lot of investigations recently showed the B lymphocytes got involvements in the squamous cell carcinoma carcinogenesis and tumor progression. In addition the B cell will influence the tumor associated macrophages and myeloid derived suppressor cells. Those immune cells could decrease the affect of chemotherapy and radiotherapy. Thus the B cell depletion has the possibility to develop a new treatment policy. Therefore investigators create a pilot clinical trial using Rituximab plus chemotherapy with cisplatin and gemcitabine for recurrent or metastatic HNSCC.
Interventions
DRUGRituximab
375mg/m2 on Day-14 and Day-7
DRUGCisplatin
70mg/m2 on Day1
DRUGGemcitabine
1000mg/m2 on Day8
Sponsors
China Medical University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed squamous cell carcinoma of head and neck. 2. Locoregional recurrence and/or metastases after primary curative local treatment and unsuitable for further radiotherapy and surgery; or primary distant metastases at diagnosis. 3. Measurable disease. Defined as presence of at least one lesion as being ≥10 mm in at least one dimension measured with conventional computed tomography (CT) or ≥10 mm in at least one dimension measured with spiral CT scan or magnetic resonance imaging (MRI) 4. Eastern Cooperative Oncology Group performance status ≤2; 5. Age between 20 and 65 years; and life expectancy of at least 12 weeks. 6. Prior treatments with radiation therapy for palliative management of non-target lesion metastatic disease is permitted provided that at least 2 weeks have relapsed since the last fraction of radiation therapy, disease progression has been documented and all treatment related adverse events are ≦ grade 1 at the time of registration. 7. Negative pregnancy test, Fertile patients must use effective contraception 8. No history of allergic reactions attributed to Rituximab/cisplatin/gemcitabine 9. Patient consent must be obtained
Exclusion criteria
1. Presence of central nervous system (CNS) metastases; 2. Presence of other malignancy with the exception of curatively treated non-melanoma skin cancer or cervical carcinoma in situ prior to entry into the study 3. Presence of bone-only metastasis 4. The organ function measured within 14 days prior to study entry as defined below: White blood cell (WBC) less than 2,000/mm3, absolute neutrophil count (ANC) less than 1,500/mm3, or platelets less than 100,000/mm3; serum bilirubin greater than 1.5 times the upper limit of normal range (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULN if no demonstrable liver metastases, or greater than 5 times the ULN in the presence of liver metastases; creatinine clearance ≤60 ml/min (based upon urine collection); 5. Concomitant illness including uncontrolled infection or other active, uncontrolled disease such as congestive heart failure, angina pectoris, respiratory insufficiency, and arrhythmia. 6. Documented hypersensitivity to platinum compounds or compounds of similar chemical or biologic composition 7. Pregnant or lactating women. 8. Under rituximab treatment or have ever received rituximab within six months. 9. Ongoing other concurrent investigational agents or anticancer therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| feasibility of the combination of Rituximab with Gemcitabin/cisplatin in R/M HNSCC | One week after Rituximab and chemotherapy administration. | Unexpected adverse event. An AE that is not listed in the drug's current labeling, or An AE that is more severe or more specific than indicated in the labeling. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | through study completion, an average of 1 years | CT scan according to the RECIST 1.1 criteria. |
| progression survival | through study completion, an average of 6 months | The time from the study registration date to the first day of disease progression at any site or of death by any cause. |
| Adverse event | through study completion, an average of 6 months | Record adverse event |
Countries
Taiwan
Outcome results
None listed